NovoCure Limited - Ordinary Shares (NVCR)
NovoCure Limited - Ordinary Shares (NVCR)
$69.39 USD
Updated Jul 19 12:00am
Add NVCR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all “A” rated Strong Buy stocks
NVCR News Stream
| Event/Time | News Detail | Start | End | Change | |||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Top Stories View All
Best & Worst Performing Stock Industries for July 19, 2019
Best & Worst Performing Small Cap Stocks for July 19, 2019
Best & Worst Performing Mid Cap Stocks for July 19, 2019
Best & Worst Performing Mega Cap Stocks for July 19, 2019
Best & Worst Performing Large Cap Stocks for July 19, 2019
View All Top StoriesNovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Stock Chart More Charts
NVCR Price/Volume Stats
| Current price | $69.39 |
| Prev. close | $71.02 |
| Day low | $68.41 |
| Day high | $72.59 |
| 50-day MA | $57.81 |
| 200-day MA | $46.56 |
| 52-week high | $72.59 |
| 52-week low | $26.02 |
| Volume | 865,000 |
| Avg. volume | 675,788 |
| Dividend yield | N/A |
| Market Cap | 6.65B |
NVCR Returns
| 1-mo | 15.73% |
| 3-mo | 60.85% |
| 6-mo | 48.84% |
| 1-year | 84.79% |
| 3-year | 480.67% |
| 5-year | N/A |
| YTD | 107.26% |
| 2018 | 65.74% |
| 2017 | 157.32% |
| 2016 | -64.89% |
| 2015 | N/A |
| 2014 | N/A |
Loading social stream, please wait...